Arbutus Biopharma (NASDAQ:ABUS) Receives Buy Rating from Chardan Capital

Chardan Capital reiterated their buy rating on shares of Arbutus Biopharma (NASDAQ:ABUS) in a research report released on Wednesday, Marketbeat Ratings reports. Chardan Capital currently has a $5.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $4.50.

ABUS has been the topic of a number of other research reports. StockNews.com upgraded Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 10th. Jefferies Financial Group upped their target price on shares of Arbutus Biopharma from $5.00 to $7.00 and gave the company a “buy” rating in a report on Thursday, September 5th. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Arbutus Biopharma in a report on Monday, November 18th. Finally, JMP Securities upped their price objective on shares of Arbutus Biopharma to $5.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $5.50.

Arbutus Biopharma Trading Up 1.4 %

NASDAQ:ABUS opened at $3.51 on Wednesday. Arbutus Biopharma has a twelve month low of $1.79 and a twelve month high of $4.72. The company has a market capitalization of $665.11 million, a P/E ratio of -8.16 and a beta of 1.92. The firm has a 50-day moving average price of $3.88 and a two-hundred day moving average price of $3.64.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ABUS. nVerses Capital LLC acquired a new position in shares of Arbutus Biopharma in the second quarter worth about $34,000. Helen Stephens Group LLC acquired a new position in shares of Arbutus Biopharma in the 3rd quarter valued at approximately $50,000. Walleye Trading LLC purchased a new position in shares of Arbutus Biopharma during the 1st quarter valued at approximately $36,000. XTX Topco Ltd purchased a new position in shares of Arbutus Biopharma during the 2nd quarter valued at approximately $53,000. Finally, Premier Path Wealth Partners LLC grew its position in shares of Arbutus Biopharma by 18.0% during the second quarter. Premier Path Wealth Partners LLC now owns 36,000 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 5,500 shares in the last quarter. 43.79% of the stock is owned by institutional investors and hedge funds.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.